Hall 406. Title: Opening & Keynote. Hall 405. Title: Treatment of node positive bladder. Hall 404

Transcription

1 :00-11:30 Type: Opening session Title: Opening & Keynote Hall :45-12:30 Type: Challenge Your Expert session Title: Treatment of node positive bladder 11:45-11:55 Treatment of node positive bladder 11:55-12:30 Discussion led by 11:45-12:30 Type: Challenge Your Expert session Title: Treatment for stage IIb cervical cancer: Surgery or chemoradiation? 11:45-11:55 Treatment for stage IIb cervical cancer: Surgery or chemoradiation? 11:55-12:30 Discussion led by 11:45-12:30 Type: Challenge Your Expert session Title: Management of early breast cancer in young women Chair: B. Xu, CN Hall :45-11:55 Management of early breast cancer in young women 11:55-12:30 Discussion led by 11:45-12:30 Type: Challenge Your Expert session Title: Skull base tumours 11:45-11:55 Skull base tumours 11:55-12:30 Discussion led by

2 11:45-12:30 Type: Challenge Your Expert session Title: What is the optimal first-line chemotherapy for advanced soft-tissue sarcoma? Chair: H. Loong, HK 11:45-11:55 What is the optimal first-line chemotherapy for advanced soft-tissue sarcoma? A. Le Cesne, CEDEX/FR 11:55-12:30 Discussion led by H. Loong, HK Title: Industry Satellite Symposium 1 Title: Industry Satellite Symposium 2 Title: Industry Satellite Symposium 3 Hall 407 Title: Industry Satellite Symposium 4 Title: Industry Satellite Symposium 5 14:30-16:00 Type: Educational session Title: Controversies in lung cancer immuno-oncology Chair: R. Califano, GB; R. Soo, SG 14:30-14:55 Immuno checkpoint blockade for advanced NSCLC: What is the role in the elderly and patients with PS2? R. Califano, GB 14:55-15:20 Immuno checkpoint blockade for oncogene-addicted NSCLC R. Soo, SG 15:20-15:45 Immuno checkpoint blockade in patients with brain metastases S. Ekman, SE 15:45-16:00 Discussion

3 14:30-16:00 Type: Educational session Title: Immunotherapy in GI cancers: Current status & future perspectives Chair: C.-H. Koehne, DE; Y.-J. Bang, KR 14:30-14:45 Biomarkers for immunotherapy B. Ma, HK 14:45-15:05 Immunotherapy in gastric cancer Y.-J. Bang, KR 15:05-15:25 Immunotherapy in hepatocellular carcinoma (HCC) T. Okusaka, JP 15:25-15:45 Immunotherapy in other GI cancers C.-H. Koehne, DE 15:45-16:00 Discussion 14:30-16:00 Type: Special Session Title: Skin toxicity Chair: C. Bokemeyer, DE 14:30-14:35 Introduction C. Bokemeyer, DE 14:35-14:55 Hair loss and management F. Boyle, AU 14:55-15:15 EGFR associated skin toxicities C. Bokemeyer, DE 15:15-15:35 Immuno-related skin reactions R. Chan, HK 15:35-15:55 Hand-foot syndrome Y.S. Yap, SG 15:55-16:00 Conclusion

4 14:30-16:00 Type: Special Session Title: Sarcoma multidisciplinary grand round 14:30-14:35 Presentation of case/condition 14:35-14:55 A 32-year old woman presenting with a large right thigh mass (high risk synovial sarcoma) A. Kawai, JP 14:55-15:15 A 32-year old man presenting with a right femoral fracture (osteosarcoma) 15:15-15:35 A 32-years old man with an acral lentiginous melanoma of the big toe with popliteal lymph node involvement R. Quek, SG 15:35-15:45 General discussion 16:30-18:00 Type: Multidisciplinary tumour board Title: Recurrent cervical cancer Chair: J.-W. Kim, KR; K. Fujiwara, JP 16:30-16:40 Presentation of case of recurrent cervical cancer J.-W. Kim, KR 16:40-17:00 Prognostic and predictive factors including human papillomavirus (HPV) H.Y.-S. Ngan, HK 17:00-17:20 Surgical considerations 17:20-17:40 Advances in systemic therapy A. Oaknin, ES 17:40-18:00 General discussion and conclusions

5 16:30-18:00 Type: Educational session Title: Rational development of immuno-oncology combinations Chair: D. Tan, SG 16:30-16:55 Non-clinical models (including immunoavatars) for development of immuno-oncology combinations 16:55-17:20 Lessons learned from immuno-oncology combinations in the clinic 17:20-17:45 Clinical trial designs, biomarkers and endpoints for immuno-oncology combinations S.-B. Kim, KR 17:45-18:00 Cancer evolution and immuno escape 16:30-18:00 Type: Multidisciplinary tumour board Title: Oligometastatic prostate cancer 16:30-16:35 Presentation of case/condition 16:35-16:55 Cutting edge science of oligometastatic R. Kanesvaran, SG 16:55-17:15 Role of surgery in oligometastatic prostate cancer J.Y. Lee, KR 17:15-17:35 ADT and chemotherapy in oligometastatic prostate cancer Y. Miura, JP 17:35-18:00 Discussion

6 09:00-10:30 Type: Educational session Title: Impact of germline genetics on current care of breast cancer Chair: S. Delaloge, FR; G. Curigliano, IT 09:00-09:25 Landscape of somatic and germline mutation in patients with breast cancer in Asia 09:25-09:50 Management of patients with BRCA1 and BRCA2 mutated early breast cancer S. Delaloge, FR 09:50-10:15 Targeting BRCA mutations and BRCAness in patients with metastatic breast cancer: Evidences from clinical trials Y.-H. Im, KR 10:15-10:30 Discussion 09:00-10:30 Type: Multidisciplinary tumour board Title: Challenges in the management of ALK positive stage III NSCLC 09:00-09:05 Presentation of case/condition 09:05-09:25 Medical oncologist s perspective B. Solomon, VIC/AU 09:25-09:45 Radiation oncologist s perspective S. Senan, NL 09:45-10:05 Thoracic surgeon s perspective 10:05-10:30 Discussion 10:00-10:45 Type: Mini Oral session Title: Mini Oral 1 11:00-12:30 Type: Proffered Paper session Title: Proffered Paper session Hall :45-12:30 Type: Mini Oral session Title: Mini Oral 1

7 Title: Industry Satellite Symposium 11 Title: Insustry Satellite Symposium 12 Title: Industry Satellite Symposium 13 Hall 407 Title: Industry Satellite Symposium 14 Title: Industry Satellite Symposium 15 14:30-16:00 Type: Educational session Title: Latest developments in urological cancers Chair: R. de Wit, NL 14:30-14:55 Metastatic prostate cancer: Optimal use of the currently available agents R. de Wit, NL 14:55-15:20 Renal cell cancer: Optimising systemic treatment in an era of emerging treatment paradigms M. Lolkema, NL 15:20-15:45 Integration of Immunotherapy in bladder cancer: Who and when to treat? M. De Santis, GB 15:45-16:00 Discussion

8 14:30-16:00 Type: Multidisciplinary tumour board Title: Multidisciplinary approach to resectable gastric cancer Chair: F. Lordick, DE; M. Terashima, JP 14:30-14:35 Presentation of case/condition F. Lordick, DE 14:35-14:55 Surgical treatment perspectives M. Terashima, Shizuoka/JP 14:55-15:15 Medical oncology perspectives C.S. Pin, SG 15:15-15:35 Is there a role for radiotherapy? T. Leong, AU 15:35-16:00 General discussion 14:30-16:00 Type: Multidisciplinary tumour board Title: Issues for cancer care in the elderly Chair: D. Keefe, AU; C. Bokemeyer, DE Hall :30-14:40 Case presentation C. Bokemeyer, DE 14:40-15:00 Assessment by onco-geriatrician 15:00-15:20 Balancing between treatment and toxicity 15:20-15:40 Managing the financial implication D. Keefe, SA/AU 15:40-16:00 Conclusions 14:30-15:15 Type: Mini Oral session Title: Mini Oral 8 15:30-16:15 Type: Mini Oral session Title: Mini Oral 2

9 16:30-18:00 Type: Educational session Title: Neurotoxicity: A problem to remember Hall :30-16:55 Peripheral neuropathy G. Cavaletti, IT 16:55-17:20 Lost in the fog: What is chemobrain? F. Boyle, AU 17:20-17:45 Acute central neurotoxicity 17:45-18:00 Discussion 16:30-17:15 Type: Mini Oral session Title: Mini Oral 4 16:30-17:15 Type: Mini Oral session Title: Mini oral 7 Room :30-18:15 Type: Mini Oral session Title: Mini oral 5 17:30-18:15 Type: Mini Oral session Title: Mini oral 1 Room :45-11:15 Type: Educational session Title: Challenges in head and neck oncology Chair: C. Le Tourneau, FR 09:45-10:10 Hyperprogression following immunotherapy: Myth or reality? C. Le Tourneau, FR 10:10-10:35 The role of plasma EBV DNA in management of nasopharyngeal cancer 10:35-11:00 Surgery for low-risk HPV positive head and neck cancer 11:00-11:20 Discussion

10 09:45-10:30 Type: Challenge Your Expert session Title: First line treatment in a fit advanced NSCLC patient with PD-L1 expression of 60% Chair: S. Lu, CN 09:45-09:55 First line treatment in a fit advanced NSCLC patient with PD-L1 expression of 60% 09:55-10:30 Discussion led by S. Lu, CN 09:45-10:30 Type: Mini Oral session Title: Mini Oral 9 10:45-11:30 Type: Challenge Your Expert session Title: Molecular biology and treatment of HCC 10:45-10:55 Molecular biology and treatment of HCC 10:55-11:30 Discussion led by 10:45-11:30 Type: Challenge Your Expert session Title: Immunotherapy vs. targeted therapy in first-line treatment of mutation positive metastatic melanomas: How does one choose? Room :45-10:55 Immunotherapy vs. targeted therapy in first-line treatment of mutation positive metastatic melanomas: How does one choose? 10:55-11:30 Discussion led by J. Guo, CN 10:45-11:30 Type: Mini Oral session Title: Mini Oral 10 11:30-12:30 Type: Industry Satellite Symposium Title: Industry Satellite Symposium 18 11:30-12:30 Type: Industry Satellite Symposium Title: Industry Satellite Symposium 19 11:30-12:30 Type: Industry Satellite Symposium Title: Industry Satellite Symposium 20 Hall 407

11 11:30-12:30 Type: Industry Satellite Symposium Title: Industry Satellite Symposium 21 11:30-12:30 Type: Industry Satellite Symposium Title: Industry Satellite Symposium 22 12:45-14:15 Type: Educational session Title: Advances in targeted therapy in gynaecological cancer Chair: K. Fujiwara, JP; A. Poveda, ES 12:45-13:10 Anti-angiogenic therapy in ovarian and endometrial cancer D. Lorusso, IT 13:10-13:35 PARP inhibitors and Synthetic Lethality in ovarian cancer E. Pujade-Lauraine, CEDEX 4/FR 13:35-14:00 Targeted therapy for treatment of cervical cancer 14:00-14:15 Discussion 12:45-14:15 Type: Multidisciplinary tumour board Title: Locally advanced nasopharyngeal carcinoma 12:45-12:55 Presentation of case/condition B. Ma, HK 12:55-13:15 Timing of chemotherapy in nasopharyngeal cancer L. Zhang, Guangdong/CN 13:15-13:35 IMRT or proton therapy M.L.K. Chua, SG 13:35-13:55 The role of surgery in the treatment of NPC 13:55-14:15 General discussion

12 14:30-16:00 Type: Special Session Title: Beyond panel based mutation profiling Chair: D. Tan, SG; M. Quintela-Fandino, ES 14:30-14:50 The maximal potential of precision medicine needs to go beyond genomic sequencing 14:50-15:10 Emerging therapeutic opportunities in the non coding genome D. Tan, SG 15:10-15:30 Unravelling resistance to multitargeted agents based on high-throughput phosphoproteomics M. Quintela-Fandino, ES 15:30-15:50 Utilizing mutational signatures to inform treatment decisions 15:50-16:00 The evolving role of molecular tumour boards 14:30-16:00 Type: Multidisciplinary tumour board Title: Management of HER2 positive early breast cancer 14:30-14:35 Presentation of case/condition 14:35-14:55 Emerging strategies in neoadjuvant treatment of patients with HER2 early breast cancer F. Cardoso, PT 14:55-15:15 Adjuvant treatment of patient with HER2+ breast cancer following neo-adjuvant chemo M. Toi, JP 15:15-15:35 Optimal surgical intervention after neoadjuvant chemotherapy 15:35-16:00 General discussion

13 14:30-16:00 Type: Educational session Title: Multidisciplinary management of retroperitoneal sarcomas Chair: A. Le Cesne, FR 14:30-14:55 The role of surgery in retroperitoneal sarcomas A. Gronchi, IT 14:55-15:20 The role of radiotherapy in retroperitoneal sarcomas R.L. Haas, NL 15:20-15:45 The role of systemic therapy in retroperitoneal sarcomas H. Loong, HK 15:45-16:00 Discussion